ABBOTT LABORATORIES (ABT) Risk Factors
Health CareLatest 10-K filed Feb 20, 2026Source: SEC EDGAR
WealthWire extracted and classified 21 risk factors from ABBOTT LABORATORIES’s latest SEC filing, mapping each to a standardized risk taxonomy so they can be compared across every company and sector. The breakdown below shows how those disclosures distribute across risk categories.
Legal & regulatory
5 factorsMarket & business
5 factorsTechnology
3 factorsOperations & people
3 factorsFinancial
3 factorsHealthcare & life sciences
1 factorsOther
1 factorsRecent key developments
Concrete developments — dated events, named agreements and instruments, legal proceedings — that ABBOTT LABORATORIES surfaced in its latest filing.
- In February 2022, Abbott initiated a voluntary recall of certain powder infant formula products manufactured at its Sturgis, Michigan facility and temporarily stopped manufacturing there.February 2022
- In May 2022, Abbott entered into a consent decree with the FDA.May 2022
- Abbott plans to fund the Exact Sciences acquisition with approximately $20 billion of borrowings.
- As of December 31, 2025, Abbott's consolidated indebtedness was approximately $12.9 billion.December 31, 2025
Go deeper on ABT
This page shows the category breakdown of the latest filing. The WealthWire API and dashboard add the full risk-factor text, multi-year trends, sector comparisons, and CSV export — for ABT and every other S&P 500 company.